Therapeutic Approaches to Autoimmunity (THER)

Late-breaking: Therapeutic Approaches to Autoimmunity

Therapeutics for Autoimmune Diseases I

Therapeutics for Autoimmune Diseases II

(555) Development and Therapeutic Evaluation of a Uniform Lymph Node Cell Transfer Model of Alopecia Areata

(556) Selective SIK2 Inhibitors Suppress Proinflammatory Responses while Upregulating Pro-Resolution Signals in Stimulated Myeloid Cells and Mice

(557) Single-cell immunoprofiling of peripheral blood in non-infectious uveitis patients receiving TNF-inhibitors

(558) Therapeutic treatment with a single CD4+ T cell epitope containing PLGA nanoparticles reverses CD8+ T Cell induced Type I Diabetes

(559) GLP-1 Receptor Agonists Ameliorate Obesity-Driven EAE Severity in HLA Class II Transgenic Mice

(560) MEK/ERK Mediated Diffuse Alveolar Hemorrhage in Murine Lupus

(562) Biodistribution of self-antigens and regulatory cues in lymph nodes induce memory-like Treg to drive antigen-specific tolerance

(563) Targeted Immunotherapy for Regulatory T Cells

(564) Deep mapping of immune responses against stem cell products in vivo for regenerative medicine

(565) A System-Level Strategy for Detecting and Tolerizing Pathogenic Autoreactive T Cells in Type 1 Diabetes

(566) The role of commensal polyomavirus in controlling lupus pathogenesis

(567) Discovery and engineering of novel IgM proteases for the treatment of autoimmune and inflammatory diseases

(569) Targeting the FOXP3–T-bet interaction to restore Treg stability in IFN-γ–driven autoimmunity

(570) Neutrophil Elastase Inhibition Prevents Neutrophil extracellular trap (NETs) Driven Autoimmune Glomerulonephritis Without Off Target Immunosuppression

(571) A New Therapeutic Strategy for Multiple Sclerosis: DRAK2 Inhibition Promotes Induction of Regulatory T Cells via Metabolic Reprogramming

(572) Therapeutic Efficacy of a Novel Oral NRF2 Activator in a Murine Ulcerative Colitis Model

(573) Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic/Safety Liabilities

(574) Novel Neuroprotective and Immunoregulatory Mechanisms for the Treatment of Multiple Sclerosis

(575) Cell-Intrinsic Role of Immune-Responsive Gene 1 (Irg1) in CD4⁺ T Cells: Implications for CNS Autoimmunity

(576) Δ8-THC–mediated PPARα activation mitigates murine autoimmune hepatitis by suppressing NLRP3 inflammasome Activity and oxidative stress

(577) A Novel Nanoparticle Strategy to Stimulate Regulatory CD8 T Cells Directly In Vivo for the Treatment of Multiple Sclerosis.

(578) P-Glycoprotein induction in Plasma cells drives treatment resistance in Lupus Nephritis via IL-17/TAK-1/C/EBP-β pathway.

(579) Modulation of Exosomes’ effects on T Cell functions

(580) SOCS1-derived mimetic peptides attenuate cytokine-induced Microglial Activation via Jak2 inhibition

(581) Targeting IRF5 with selective covalent oral small molecules attenuates Type I IFN and pro-inflammatory cytokine secretion in human PBMCs and in mice

(582) Chemical Probes Targeting CTLA-4: Building the Foundation for Non-Antibody Immune Modulattors

(583) Engineered regulatory T cells (eTregs) for the treatment of type 1 diabetes

(584) HLA Gene Editing of the Type I Diabetes Susceptible DQ8 Allele Inhibits Hybrid Insulin Peptide Binding and T Cell Activation

(700) Targeting Novel DNase Therapeutic to Intracellular cGAS–STING Pathway for DNA Clearance in TREX1-Deficient Aicardi-Goutières Syndrome

(701) A CD19/BCMA Dual-targeting VHH format T-cell Engager with Novel CD3 Binder for Enhanced Potency and Safety Profile

(702) AI/ML-Accelerated Discovery of Oral α4β7 Integrin Inhibitors for Treating Inflammatory Bowel Disease

(703) S-4321 IS A NOVEL, NON-DEPLETING, BIFUNCTIONAL PD-1:FcγRIIB SELECTIVE AGONIST ANTIBODY FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES

(704) Discovery of highly potent and selective VAV1 molecular glue degraders for the treatment of inflammatory disorders

(705) Prolonged IL-10 Exposure Modulates Adaptive and Innate Immune Responses in Secondary Lymphoid Organs during Experimental Autoimmune Encephalomyelitis

(706) Decoding Antigen-specific Tolerance Mechanisms Imposed by an MHC-II targeted Nanobody-based Therapy for Multiple Sclerosis

(707) A novel hydrophilic nanoparticle mRNA-based platform to deliver antigen-specific immune therapies in autoimmune diseases

(708) LatY136F mice: a preclinical model for IgG4-related disease and autoimmune disorders

(710) An allogeneic CD19 targeted Engineered Treg approach for treating B cell mediated autoimmune diseases

(711) A novel mice colitis model recapitulates human T cell and myeloid cell reconstitution to Support drug evaluation of inflammatory bowel disease

(712) Pharmacological activation of LANCL2 is a novel immunometabolic mechanism for the treatment of psoriasis

(713) Limosilactobacillus reuteri-educated T cells protect against activation of liver inflammation in immunocompromised mice

(714) Treatment Effect of CD40 Inhibition in Combination with Duoconjugates in a Mouse Model of Myasthenia Gravis

(715) ES302, A Novel TL1A/IL-23p19 Bi-specific Antibody Demonstrates Robust Efficacy and Developability for Inflammatory Bowel Disease

(716) Lipid Nanoparticle-Encapsulated mRNA-Targeting CD19 for B and Plasma Cell Depletion in Autoimmune Diseases

(717) Activating Inflammation Resolution Programs Improves Immunosuppressive Therapy and Prevents Toxicity in Autoimmune Bone Marrow Failure

(718) Heligmosomoides polygyrus bakeri secretions (HES) promote Treg differentiation and inhibit pathogenesis in a mouse model of vitiligo

(719) Therapeutic antigen-specific PLGA nanoparticles tolerance induces detectable changes in the spleen, blood, and disease-associate tissue

(720) Treatment with male gut microbiota or metabolite downregulates gene expression associated with inflammation in kidneys of lupus-prone mice

(721) Cytokine changes following methotrexate treatment in rat adjuvant-induced arthritis

(722) Generation of plasma cell targeting OR-gated CAR T cells for the treatment of autoimmune disease

(723) Potent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humans

(724) Characterization of endoglycosidase enzymes for treating autoimmune and inflammatory diseases

(725) CD2 x IL2RG bispecific antibodies synergistically modulate lymphocyte activation, resulting in suppression of inflammation and prevention of GVHD

(726) BTK Inhibition Resets Pathological B and T cell Subsets in Patients with IgG4-Related Disease

(727) Therapeutic treatment with PD-1 agonist antibody prevents progressive autoantibody increase in murine autoimmune disease models

(728) Purinergic receptor P2X7R regulates neuropsychiatric lupus.

(729) Discovery of a FcgRIIb agonist antibody for treatment of autoimmune and inflammatory diseases

(731) S-1117, an engineered pan-IgG cleaving enzyme, reduces IgG BCR mediated B cell activation and removes Fc fragments from tissue-bound anti-AChR IgG

(733) CUE-401 is a Novel TGF-beta/IL-2 Fusion Protein that Induces Selective Expansion of Functional, Stable FOXP3+ Tregs for Treatment of Autoimmunity

(734) Beyond Transcription: T cell-Intrinsic IRF5 Regulates Metabolism and Post-Transcriptional Responses in Autoimmunity

(735) De Novo Design of Alpha-Synuclein Fibrils Inhibitors for Treating Parkinson’s Disease

(736) Exploring Female Obesity and Type 1 Interferon Signaling in the Context of Multiple Sclerosis